Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing-based analysis for hemophilia: experience from a hemophilia treatment center in China

被引:1
作者
Shi, Meizhen [1 ]
Ma, Yunting
Peng, Xianwei
Zhou, Xu
Cheng, Zifeng
Xie, Bobo [1 ]
Wei, Xianda [1 ]
Gui, Chunrong [1 ]
Mao, Aiping
Lin, Wenting [1 ]
Luo, Jiefeng [5 ]
Lai, Yinghui [4 ]
Gui, Baoheng [1 ,2 ,3 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 2, Ctr Med Genet & Genom, 166 Daxuedong Rd, Nanning 530007, Guangxi Zhuang, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 2, Guangxi Hlth Commiss Key Lab Med Genet & Genom, Nanning, Guangxi Zhuang, Peoples R China
[3] Guangxi Med Univ, Sch Med 2, Nanning, Guangxi Zhuang, Peoples R China
[4] Guangxi Med Univ, Affiliated Hosp 2, Dept Hematol, 166 Daxuedong Rd, Nanning 530007, Guangxi Zhuang, Peoples R China
[5] Guangxi Med Univ, Affiliated Hosp 2, Dept Neurol, 166 Daxuedong Rd, Nanning 530007, Guangxi Zhuang, Peoples R China
基金
中国国家自然科学基金;
关键词
breakpoint mapping; clinical applicability; gene variants; hemophilia; targeted long-read sequencing; (LRS); FACTOR-VIII; INHIBITOR DEVELOPMENT; MUTATION LIST; REARRANGEMENTS; GENE; RECOMMENDATION; MECHANISMS; GUIDELINES; MANAGEMENT; DIAGNOSIS;
D O I
10.1016/j.jtha.2024.08.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Targeted long-read sequencing (LRS) is expected to comprehensively analyze diverse complex variants in hemophilia A (HA) and hemophilia B (HB) caused by the F8 and F9 genes, respectively. However, its clinical applicability still requires extensive validation. Objectives: To evaluate the clinical applicability of targeted LRS-based analysis compared with routine polymerase chain reaction (PCR)-based methods. Methods: Gene variants of retrieved subjects were retrospectively and prospectively analyzed. Whole-genome sequencing was performed to further analyze undiagnosed cases. Breakpoints of novel genomic rearrangements were mapped and validated using long-distance PCR and long-range PCR combined with sequencing. Results: In total, 122 subjects were retrieved. In retrospective analysis of the 90 HA cases, HA-LRS assay showed consistent results in 84 cases compared with routine methods and characterized 6 large deletions with their exact breakpoints confirmed by further validation in 6 cases (routine methods only presented failure in amplifying the involved exons). In prospective analysis of the 21 HA subjects, 20 variants of F8 were identified in 20 cases. For the remaining HA patient, no duplication/deletion or single-nucleotide variant (SNV)/insertion and deletion (InDel) was found, but a potential recombination involving exons 14 and 21 of F8 was observed by LRS. Wholegenome sequencing analysis and further verification defined a 30 478 base pairs (bp) tandem repeat involving exons 14 to 21 of F8. Among the 11 HB patients, HB-LRS analysis detected 11 SNVs/InDels in F9, consistent with routine methods. Conclusion: Targeted LRS-based analysis was efficient and comprehensive in identifying SNVs/InDels and genomic rearrangements of hemophilia genes, especially when we first expanded the panel to include F9. However, further investigation for complex gross rearrangement is still essential.
引用
收藏
页码:3431 / 3447
页数:17
相关论文
共 47 条
  • [31] Comprehensive Analysis of Congenital Adrenal Hyperplasia Using Long-Read Sequencing
    Liu, Yingdi
    Chen, Miaomiao
    Liu, Jing
    Mao, Aiping
    Teng, Yanling
    Yan, Huiming
    Zhu, Huimin
    Li, Zhuo
    Liang, Desheng
    Wu, Lingqian
    [J]. CLINICAL CHEMISTRY, 2022, 68 (07) : 927 - 939
  • [32] Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients
    Ljung, Rolf
    Auerswald, Guenter
    Benson, Gary
    Dolan, Gerry
    Duffy, Anne
    Hermans, Cedric
    Jimenez-Yuste, Victor
    Lambert, Thierry
    Morfini, Massimo
    Zupancic-Salek, Silva
    Santagostino, Elena
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (02) : 111 - 122
  • [33] Genomic disorders: structural features of the genome can lead to DNA rearrangements and human disease traits
    Lupski, JR
    [J]. TRENDS IN GENETICS, 1998, 14 (10) : 417 - 422
  • [34] Complete F9 Gene Deletion, Duplication, and Triplication Rearrangements: Implications for Factor IX Expression and Clinical Phenotypes
    Ma, Yuxin
    Li, Yang
    Sun, Jie
    Liang, Qian
    Wu, Runhui
    Ding, Qiulan
    Dai, Jing
    [J]. THROMBOSIS AND HAEMOSTASIS, 2024, 124 (04) : 374 - 385
  • [35] Environmental and genetic factors influencing inhibitor development
    Oldenburg, J
    Schröder, J
    Brackmann, HH
    Müller-Reible, C
    Schwaab, R
    Tuddenham, E
    [J]. SEMINARS IN HEMATOLOGY, 2004, 41 (01) : 82 - 88
  • [36] Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens
    Oldenburg, Johannes
    [J]. BLOOD, 2015, 125 (13) : 2038 - 2044
  • [37] The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource
    Payne, Amanda B.
    Miller, Connie H.
    Kelly, Fiona M.
    Soucie, J. Michael
    Hooper, W. Craig
    [J]. HUMAN MUTATION, 2013, 34 (02) : E2382 - E2391
  • [38] The past and future of haemophilia: diagnosis, treatments, and its complications
    Peyvandi, Flora
    Garagiola, Isabella
    Young, Guy
    [J]. LANCET, 2016, 388 (10040) : 187 - 197
  • [39] Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
    Richards, Sue
    Aziz, Nazneen
    Bale, Sherri
    Bick, David
    Das, Soma
    Gastier-Foster, Julie
    Grody, Wayne W.
    Hegde, Madhuri
    Lyon, Elaine
    Spector, Elaine
    Voelkerding, Karl
    Rehm, Heidi L.
    [J]. GENETICS IN MEDICINE, 2015, 17 (05) : 405 - 424
  • [40] Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis
    Rosendaal, Frits R.
    Palla, Roberta
    Garagiola, Isabella
    Mannucci, Pier M.
    Peyvandi, Flora
    [J]. BLOOD, 2017, 130 (15) : 1757 - 1759